OncoMatch/Clinical Trials/NCT06760039
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
Is NCT06760039 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including R-CMOP Regimen and R-CHOP Regimen for diffuse large b-cell lymphoma.
Treatment: R-CMOP Regimen · R-CHOP Regimen — This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Demographics
Prior therapy
Cannot have received: antitumor therapy
Lab requirements
Blood counts
sufficient bone marrow function
Kidney function
sufficient kidney function
Liver function
sufficient liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06760039 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify